Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Nodexus has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Nodexus's investors include RA Capital Management, National Science Foundation, S32, SkyDeck Berkeley, Astia Angels.
Nodexus is headquartered in San Jose, United States.
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Nodexus is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nodexus — Funding & Investors." VCBacked, December 16, 2021, https://www.vcbacked.co/company/nodexus. Accessed August 14, 2026.
VCBacked. (2021). Nodexus — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nodexus
{{cite web |title=Nodexus — Funding & Investors |url=https://www.vcbacked.co/company/nodexus |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated